Shepherd J D, Shore T B, Reece D E, Barnett M J, Klingemann H G, Buskard N A, Phillips G L
Leukemia/Bone Marrow Transplantation Program, British Columbia, Vancouver, Canada.
Bone Marrow Transplant. 1988 Nov;3(6):553-8.
Twenty-eight consecutive HLA matched patients undergoing allogeneic bone marrow transplantation received prophylaxis for acute graft-versus-host disease with combined cyclosporine and methylprednisolone. The incidence of grades II-IV acute GVHD was 28.5%, a figure similar to that reported for two other drug regimens. The incidence of chronic GVHD in patients surviving longer than 150 days was 73%. Toxicity, especially renal, was acceptable and a number of potential problems associated with the use of methotrexate were avoided. While this regimen and similar ones have reduced the incidence and severity of acute GVHD the problem remains formidable and newer approaches are clearly needed.
28例接受异基因骨髓移植且HLA配型相合的连续患者接受了环孢素与甲泼尼龙联合预防急性移植物抗宿主病的治疗。Ⅱ-Ⅳ级急性移植物抗宿主病的发生率为28.5%，这一数字与其他两种药物方案所报告的相似。存活超过150天的患者中慢性移植物抗宿主病的发生率为73%。毒性，尤其是肾脏毒性是可接受的，并且避免了与使用甲氨蝶呤相关的一些潜在问题。虽然该方案及类似方案已降低了急性移植物抗宿主病的发生率和严重程度，但问题仍然严峻，显然需要更新的方法。
